Reconstruction Special Edition, Issue 2
The following three articles comprise the second edition of a special series highlighting important aspects of Head and Neck Reconstruction. These peer-reviewed papers highlight current standards, unique practices, and quality and value projects within our field of head and neck reconstruction. The articles are grouped into three different categories: 1) Subsite reconstruction 2) Versatile microvascular free flaps and 3) Perioperative considerations. (Source: Oral Oncology)
Source: Oral Oncology - December 1, 2017 Category: Cancer & Oncology Authors: Matthew Old Source Type: research
Editorial Board/Aims & Scope
(Source: Oral Oncology)
Source: Oral Oncology - December 1, 2017 Category: Cancer & Oncology Source Type: research
RACK1 is an organ-specific prognostic predictor in OSCC
OSCC is one of the most common subtypes of HNSCC, with an estimated 300,000 new cases and 140,000 deaths occurring worldwide each year [1]. The five-year survival rate of patients with OSCC is only about 50%, despite recent advances in diagnosis and treatment [2]. Now, the most significant factors to affect outcome of patients with OSCC are still the classical clinic pathological parameters of tumor such as tumor stage, and clinical TNM stage, which are not possible to be good predictors of the risk of death. (Source: Oral Oncology)
Source: Oral Oncology - November 29, 2017 Category: Cancer & Oncology Authors: Sai Liu, JiaJia Liu, Jiongke Wang, Junxin Cheng, Xin Zeng, Ning Ji, Jing Li, Qianming Chen Source Type: research
Benzethonium chloride activates ER stress and reduces proliferation in HNSCC
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in the world, accounting for 650,000 new cancer diagnoses each year with 350,000 deaths [1]. Despite the high mortality rate and increased public interest in the United States, NIH support for head and neck cancer research has been decreasing and progress in treatments has accordingly lagged egregiously behind more generously funded malignancies [2 –4]. Management of HNSCC over the past 20 years has moved towards an organ preservation approach with most patients being offered a combination of chemotherapy and radiation treatment. (Source: Oral Oncology)
Source: Oral Oncology - November 29, 2017 Category: Cancer & Oncology Authors: Hani M. Rayess, Yue Xi, Danielle M. Garshott, Amy L. Brownell, George H. Yoo, Michael U. Callaghan, Andrew M. Fribley Source Type: research
Erratum to “Reconstruction design before tumour resection: A new concept of through-and-through cheek defect reconstruction” [Oral Oncol. 74 (2017) 123–129]
The publisher regrets that the First Author ’s appears incorrectly in the publication. The First Author name should appear as above. (Source: Oral Oncology)
Source: Oral Oncology - November 24, 2017 Category: Cancer & Oncology Authors: Zhao-Jian Gong, Zhen-Hu Ren, Kai Wang, Hong-Yu Tan, Sheng Zhang, Han-Jiang Wu Tags: Erratum Source Type: research
Optimising volumetric arc radiotherapy for dental rehabilitation in oropharynx cancer – A retrospective dosimetry review and feasibility planning study
Squamous cell carcinomas (SCC) of the oropharynx are potentially curable cancers with surgery, radiotherapy, chemoradiotherapy or a combination of the same [1]. Three year survival rates up to 82% are reported, and are best in Human Papilloma Virus (HPV) related disease [2], meaning that survivorship issues are now increasingly important. In a UK head and neck cancer follow up clinic almost 30% of patients complained of ongoing dental issues relating to pain as well as poor functional dental consequences, reported by both dentate and edentulous patients [3]. (Source: Oral Oncology)
Source: Oral Oncology - November 23, 2017 Category: Cancer & Oncology Authors: Sean M. O'Cathail, Naveen Karir, Ketan Shah Source Type: research
Pre-diagnostic dynamic HPV16 IgG seropositivity and risk of oropharyngeal cancer: Methodological issues
We were interested to read the paper authored by Anderson and colleagues that was published in the journal of Oral Oncology in October 2017 [1]. The authors aimed to examine the association of HPV16 antibodies (Abs) and oropharyngeal cancer (OPC) risk in sera obtained prior to clinical diagnosis. They found that Abs to E2 were strongly associated with cases 0 –2 years pre- diagnosis (odds ratio (OR): 150.1; 95% confidence interval (CI): 27.4–1040.0) and HPV status (OR: 35.6; 95% CI: 8.7–200.0). Although their study makes valuable contribution to the area, some methodological issues need to be taken into account. (Source: Oral Oncology)
Source: Oral Oncology - November 22, 2017 Category: Cancer & Oncology Authors: Erfan Ayubi, Saeid Safiri Tags: Letter to the editor Source Type: research
Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site
Oral cavity and pharyngeal cancers (OCPC) include cancers of the lip, oral cavity, and pharynx. Together, this group of cancers accounts for over 500,000 new cancer cases per year worldwide [1]. In 2007, the WHO concluded that human papillomavirus (HPV) type 16 is a cause of some subtypes of OCPC [2]. Many epidemiological and molecular studies have meanwhile provided evidence for this causal link, particularly for squamous cell cancers of the oropharynx, the tonsils and parts of the tongue [3]. Consequently, a paradigm shift in the understanding of OCPC has occurred. (Source: Oral Oncology)
Source: Oral Oncology - November 21, 2017 Category: Cancer & Oncology Authors: L. Jansen, N. Buttmann-Schweiger, S. Listl, M. Ressing, B. Holleczek, A. Katalinic, S. Luttmann, K. Kraywinkel, H. Brenner, for the GEKID Cancer Survival Working Group Source Type: research
Nanomedicine, an emerging therapeutic strategy for oral cancer therapy
Squamous Cell Carcinoma (SCC) is the most frequently diagnosed oral cancer. It is important to note that while this term is oftentimes used to include both oral cavity and oropharyngeal SCC tumors, these are both separate entities [1,2]. Both are included within the larger group of Head and Neck Squamous Carcinoma (HNSCC), which is the sixth most common form of cancer worldwide [3]. Herein, the term oral SCC (OSCC) is used in reference to both SCC of the oral cavity and oropharynx. OSCC represents ∼2 to 3% of all human cancers [4]. (Source: Oral Oncology)
Source: Oral Oncology - November 20, 2017 Category: Cancer & Oncology Authors: Sabrina Marcazzan, Elena Maria Varoni, Elvin Blanco, Giovanni Lodi, Mauro Ferrari Tags: Review Source Type: research
Psychometric validation of the Center for Epidemiological Studies Depression Scale in Head and Neck Cancer patients
Depression is a common complication in patients with cancer [1]. Studies have shown that patients with head and neck cancer (HNC) experience higher rates of depression than other groups with an incidence of 15 –50% as compared to 15–25% in other cancers [2]. Depression associated with cancer treatment in HNC patients has also been shown to contribute to lower quality of life, high levels of fatigue, low motivation, and higher suicide rates [2]. Early detection of depression and treatment would facilit ate better treatment outcomes and quality of life [3]. (Source: Oral Oncology)
Source: Oral Oncology - November 15, 2017 Category: Cancer & Oncology Authors: K.S. Chhabria, G.D. Carnaby Source Type: research
Definitive (chemo)radiotherapy is a curative alternative for standard of care in advanced stage squamous cell carcinoma of the oral cavity
Head and neck squamous cell carcinoma is the 7th most common cancer in men and the 9th most common cancer in women in The Netherlands. Per year, 900 out of 2900 head and neck cancer patients are diagnosed with oral cavity carcinoma (OCC) [1]. Although there has been a shift towards organ preservation treatment in other head and neck cancer subsites [2], the standard of care for advanced oral cavity cancer is surgery with adjuvant (chemo)radiotherapy (CRT). However, especially in patients with locally advanced disease, this surgery may lead to extensive mutilation and results in a disappointing 5-year overall survival of 65...
Source: Oral Oncology - November 15, 2017 Category: Cancer & Oncology Authors: Joris B.W. Elbers, Abrahim Al-Mamgani, Danique Paping, Michiel W.M. van den Brekel, Katarzyna J óźwiak, J.P. de Boer, Baris Karakullukcu, Marcel Verheij, Charlotte L. Zuur Source Type: research
Hypermethylated ZNF582 and PAX1 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer
The estimated annual incidence of oral squamous cell carcinoma (OSCC) is approximately 275,000 new cases worldwide. OSCC is the eighth most prevalent cancer in the world [1]. In Taiwan, OSCC ranks fifth among the predominant cancers for both sexes and accounts for the fourth most common cancer for males [2]. Development of recurrent cancer and second primary cancer is one of the major causes of the poor 5-year overall survival of OSCC patients [3]. Therefore, it is crucial to find a biomarker that can predict the progression, recurrence, and prognosis of OSCC at its earliest stage. (Source: Oral Oncology)
Source: Oral Oncology - November 15, 2017 Category: Cancer & Oncology Authors: Shih-Jung Cheng, Chi-Feng Chang, Hui-Hsin Ko, Yi-Ching Liu, Hsin-Hui Peng, Huei-Jen Wang, Hsiao-Shan Lin, Chun-Pin Chiang Source Type: research
Differential roles of kallikrein-related peptidase 6 in malignant transformation and ΔNp63β-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) accounts for approximately 3% of all malignancies worldwide [1]. Due to a high rate of local invasion and recurrence, the overall survival rate of OSCC patients has failed to substantially rise over the last decade [2]. Especially, locally advanced OSCC remains refractory and lethal in more than 50% cases [1]. Distant metastases are rarely found on initial presentation; therefore, locoregional disease control and the elucidation of the mechanism underlying OSCC invasion are critical to improving the survival rate of OSCC patients [3]. (Source: Oral Oncology)
Source: Oral Oncology - November 14, 2017 Category: Cancer & Oncology Authors: Naoki Kaneko, Shintaro Kawano, Kaori Yasuda, Yuma Hashiguchi, Taiki Sakamoto, Ryota Matsubara, Yuichi Goto, Teppei Jinno, Yasuyuki Maruse, Masahiko Morioka, Taichi Hattori, Shoichi Tanaka, Hideaki Tanaka, Tamotsu Kiyoshima, Seiji Nakamura Source Type: research
Cancer stem cell and its niche in malignant progression of oral potentially malignant disorders
Oral cancer, which is the sixth most common cancer, accounts for 300,000 cases worldwide [1]. A large proportion of oral cancer is preceded by the development of oral leukoplakia [2,3], an oral potentially malignant disorder (OPMD). The histologic progression of OPMD from hyperplasia, different grades of dysplasia to carcinoma-in-situ and invasive carcinoma and the associated genomic changes are well studied [4]. Cancer stem cells (CSCs) have been increasingly implicated in oral carcinogenesis and field cancerization [5], and are known to be regulated by stroma and endothelial cells constituting the CSC-niche [6,7]. (Source: Oral Oncology)
Source: Oral Oncology - November 11, 2017 Category: Cancer & Oncology Authors: Subin Surendran, Gangotri Siddappa, Amrutha Mohan, Wesley Hicks, Vijayvel Jayaprakash, Christina Mimikos, Mohammed Mahri, Fatima Almarzouki, Kayla Morrell, Ravindra Ravi, Sindhu Govindan, C.N. Sushma, Nisheena Raghavan, Praveen Birur, Jeyaram Ilayaraja, M Source Type: research
Unplanned readmission following transoral robotic surgery
The Hospital Readmissions Reduction Program (HRRP), established by the Affordable Care Act, aims to reduce unplanned hospital readmissions by 20% and requires the Centers for Medicare and Medicaid Services to reduce payments to hospitals that do not meet a certain national benchmark for acceptable readmission rates [1]. Although head and neck oncologic procedures are not yet included in the HRRP, future expansion or iterations may affect otolaryngologists. Moreover, unplanned readmission negatively affects patient quality of life [2]. (Source: Oral Oncology)
Source: Oral Oncology - November 11, 2017 Category: Cancer & Oncology Authors: Michael C. Topf, Amanda Vo, Patrick Tassone, Christopher Shumrick, Adam Luginbuhl, David M. Cognetti, Joseph M. Curry Source Type: research
